NICE CG181 Cardiovascular disease: risk assessment and reduction, including lipid modification

This NICE guideline on cardiovascular disease (CVD) was updated in February 2023 and covers the assessment and care of adults who are at risk of or have CVD. It makes four recommendations covering:

• Identifying and assessing cardiovascular disease (CVD) risk
• Aspirin for primary prevention of CVD
• Lifestyle modifications for the primary and secondary prevention of CVD
• Lipid modification therapy for the primary and secondary prevention of CVD

It aims to help healthcare professionals identify people at risk of CVD, including people with type 1 or type 2 diabetes, or chronic kidney disease, with advice on how lifestyle changes and statins can be used to reduce the risk. In February 2023, a new recommendation was added on aspirin for the primary prevention of CVD.

For more information, please visit the NICE website.